Efficacy and safety of neoadjuvant therapy combined with immunotherapy in MMR‑proficient/microsatellite stable non‑metastatic rectal cancer: a systematic review and meta‑analysis.

J Cancer Res Clin Oncol · 2025 · PMC12705497 · PMID 41396282

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

In addition, the cCR rate in the SCRT group was 25% (95% CI: 0.18–0.33, p < 0.001), compared to only 15% (95% CI: 0.07–0.24, p < 0.001) in the LCRT group; although the difference did not reach conventional statistical significance, it showed a trend ( p = 0.08) (Fig. 4 c).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.